GHRP-6 for muscle growth: what the evidence actually says

What did @hormone.market actually say?

Honestly? Not much that's medically decipherable. The transcript reads: "A lot of people have made money and the money is there, I'm getting it sweet and I want to get it. I'm going to find out if I put it on the vehicle and I think this is a lot better so." That is the entire spoken content. There are no specific dosing claims, no mechanism explanations, no direct health promises tied to a named compound. The hashtag #ghrp6 is the only real signal that this is about a growth hormone releasing peptide.

The phrase "put it on the vehicle" is the one fragment worth examining. In peptide circles, "vehicle" typically refers to a carrier solution or delivery method, such as bacteriostatic water for reconstitution or a topical carrier. Whether that's what they meant here is genuinely unclear. The video's context sits alongside #gaming and #mk11fatalities hashtags, which makes the intended audience and message even murkier.

Does the science back this up?

There's no coherent scientific claim to evaluate here, which is itself a problem. GHRP-6 is a real synthetic hexapeptide that stimulates ghrelin receptors and triggers growth hormone release. The research exists, but it's mostly animal studies and small human trials. None of it is being referenced in this video.

What we do know from the literature: GHRP-6 demonstrably stimulates GH secretion in humans (Laron et al., 1995, Clinical Endocrinology). It also significantly increases appetite via ghrelin pathway activation, which matters for anyone using it for body composition purposes. A 2009 review in Growth Hormone and IGF Research by Bowers noted that GHRP-6 combined with growth hormone releasing hormone (GHRH) analogs produces synergistic GH release. The problem is that jumping from "it raises GH in a lab setting" to "it helps you get gains at the gym" involves several inferential leaps the video doesn't bother to flag.

The delivery method question, the "vehicle" comment, is actually more scientifically relevant than it sounds. GHRP-6 has poor oral bioavailability and is typically administered subcutaneously. A topical vehicle formulation would face real absorption barriers that current evidence doesn't support well.

What did they get wrong (or right)?

They didn't get much wrong in the traditional sense because they didn't actually say anything specific enough to be wrong. That is its own kind of problem. Vague content paired with a peptide hashtag and gym culture framing sends implicit signals without making falsifiable statements. That's a strategy, not an accident.

The "vehicle" framing is where a legitimate concern lives. If this is implying topical GHRP-6 application is effective, that's not supported by current evidence. Peptide absorption through intact skin is a well-documented challenge. Peptides above roughly 500 daltons face significant skin permeation barriers (Benson, 2012, Expert Opinion on Drug Delivery). GHRP-6 sits at approximately 873 daltons. No robust human data supports meaningful systemic effect from topical GHRP-6 at this time.

What they got right, inadvertently: GHRP-6 is a real compound with real pharmacological activity. The interest in it from gym communities isn't invented from nothing. The problem is the gap between "pharmacologically active" and "proven safe and effective for your goals" is enormous, and this video doesn't acknowledge it exists.

What should you actually know?

GHRP-6 is not FDA-approved for general use. It exists in a gray zone where compounding pharmacies may prepare it under specific circumstances, but it is not a regulated therapeutic with an established safety profile in long-term human use. Anyone considering it should be doing so under medical supervision with a provider who can monitor GH and IGF-1 levels.

The appetite stimulation effect is substantial and often underreported in gym content. Studies show GHRP-6 can meaningfully increase caloric intake, which complicates its use for people with body composition goals that don't involve caloric surplus (Laferrere et al., 2005, Journal of Clinical Endocrinology and Metabolism).

• GHRP-6 requires subcutaneous injection for reliable bioavailability. Topical or oral claims should be viewed with skepticism.
• Peptides sourced outside regulated telehealth channels carry contamination and concentration risks that are not theoretical.
• Combining GHRP-6 with other GH secretagogues amplifies both effects and risks, and no combination protocol has been tested in long-term human safety trials.
• If a provider cannot explain the pharmacokinetics and monitoring plan for a peptide they're prescribing, that's a red flag worth taking seriously.